Skip to main content

Table 1 A Comparison of baseline characteristics of the participant

From: Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial

 

BBIBP-CorV

n = 242

RCP

n = 241

Total

n = 483

Sex, n (%)

 Male

162 (66.9)

167 (69.3)

329 (68.1)

 Female

80 (33.1)

74 (30.7)

154 (31.9)

Age, years

 Mean (SD)

51.94 (14.5)

51.95 (13.3)

51.94 (13.9)

Age group, n (%)

 18–28

12 (5.0)

15 (6.2)

27 (5.6)

 28–38

37 (15.3)

30 (12.5)

67 (13.9)

 38–48

44 (18.2)

40 (16.6)

84 (17.4)

 48–58

63 (26.0)

69 (28.6)

132 (27.3)

 58–68

70 (28.9)

69 (28.6)

139 (28.8)

 > 68

15 (6.2)

18 (7.5)

33 (6.8)

Body mass index

 Mean (SD)

27.09 (4.0)

27.42 (4.3)

27.25 (4.2)

Education, n (%)

 No formal education

26 (10.7)

17 (7.1)

43 (8.9)

 Up to diploma

62 (25.6)

72 (29.9)

134 (27.7)

 Diploma

58 (24.0)

69 (28.6)

127 (26.3)

 Diploma plus

26 (10.7)

11 (4.6)

37 (7.7)

 Bachelor

44 (18.2)

47 (19.5)

91 (18.8)

 Master

23 (9.5)

15 (6.2)

38 (7.9)

 Doctoral and above

3 (1.2)

10 (4.2)

13 (2.7)

Comorbidities n (%)

 Hypertension

36 (14.9)

38 (15.8)

74 (15.3)

 Chronic heart diseases

5 (2.1)

5 (2.1)

10 (2.1)

 Chronic non-asthma lung diseases

0 (0.0)

2 (0.8)

2 (0.4)

 Asthma

4 (1.7)

3 (1.2)

7 (1.5)

 Chronic kidney diseases

1 (0.4)

0 (0.0)

1 (0.2)

 Moderate or severe liver diseases

1 (0.4)

1 (0.4)

2 (0.4)

 Mild liver diseases (fatty liver)

10 (4.1)

13 (5.4)

23 (4.8)

 Chronic neurological diseases

3 (1.2)

4 (1.7)

7 (1.5)

 Diabetes

21 (8.7)

25 (10.4)

46 (9.5)

 Diabetes with complications

0 (0.0)

1 (0.4)

1 (0.2)

 Chronic blood diseases

0 (0.0)

1 (0.4)

1 (0.2)

 Rheumatic diseases

1 (0.4)

0 (0.0)

1 (0.2)

 Dementia

0 (0.0)

0 (0.0)

0 (0.0)